Altium Capital Takes 9.99% Stake in Cyclacel Pharma

TL;DR

**Altium Capital just bought nearly 10% of Cyclacel, big vote of confidence!**

AI Summary

Altium Capital Management, LP, a New York-based investment firm, reported acquiring a significant stake in Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC), a pharmaceutical company. As of December 21, 2023, Altium Capital Management LP beneficially owns 1,460,000 shares of Cyclacel's common stock, representing 9.99% of the company's outstanding shares. This substantial investment signals Altium's confidence in Cyclacel's future, which could be seen as a positive indicator for current and prospective shareholders.

Why It Matters

A major institutional investor taking a nearly 10% stake can signal strong belief in the company's prospects, potentially boosting investor confidence and stock price.

Risk Assessment

Risk Level: low — This filing indicates a significant investment by an institutional fund, generally seen as a positive signal rather than a risk.

Analyst Insight

A smart investor would view this as a positive signal, potentially indicating that a sophisticated investor sees value in Cyclacel. It might warrant further research into Cyclacel's fundamentals and recent news, especially given the significant stake taken by Altium Capital Management, LP.

Key Numbers

• 1,460,000 — Shares Beneficially Owned (Represents the total number of Cyclacel Pharmaceuticals, Inc. common stock shares held by Altium Capital Management, LP.)
• 9.99% — Percentage of Class (Indicates the significant ownership stake Altium Capital Management, LP has in Cyclacel Pharmaceuticals, Inc.)
• December 21, 2023 — Date of Event (The specific date when Altium Capital Management, LP's ownership reached the threshold requiring this SC 13G filing.)

Key Players & Entities

• Altium Capital Management, LP (company) — the reporting person acquiring shares
• Cyclacel Pharmaceuticals, Inc. (company) — the subject company whose shares were acquired
• 1,460,000 shares (dollar_amount) — the total number of shares beneficially owned by Altium Capital Management, LP
• 9.99% (dollar_amount) — the percentage of Cyclacel's common stock beneficially owned by Altium Capital Management, LP
• December 21, 2023 (person) — the date of the event requiring the filing

Forward-Looking Statements

• Cyclacel Pharmaceuticals, Inc. stock price may see a short-term positive reaction due to increased institutional investor confidence. (Cyclacel Pharmaceuticals, Inc.) — medium confidence, target: Q1 2024
• Altium Capital Management, LP may increase its stake further or engage with Cyclacel's management. (Altium Capital Management, LP) — low confidence, target: Q2 2024

FAQ

Key Financial Figures

• $0.001 — ame of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securiti

Filing Documents

• cycc-sc13g_122123.htm (SC 13G) — 84KB
• ex-1.htm (EX-1) — 11KB
• 0001999371-24-000308.txt ( ) — 96KB

(a)

Item 1(a). Name of Issuer: Cyclacel Pharmaceuticals, Inc.. (the "Issuer")

(b)

Item 1(b). Address of Issuer's Principal Executive Offices: 200 Connell Drive, Suite 1500 Berkeley Heights, NJ 07922

(a)

Item 2(a). Name of Person Filing: This statement is jointly filed by and on behalf of each of Altium Growth Fund, LP (the "Fund"), Altium Capital Management, LLC, and Altium Growth GP, LLC. The Fund is the record and direct beneficial owner of the securities covered by this statement. Altium Capital Management, LP is the investment adviser of, and may be deemed to beneficially own securities, owned by the Fund. Altium Growth GP, LLC is the general partner of, and may be deemed to beneficially own securities, owned by the Fund. Each reporting person declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, the beneficial owner of any securities covered by this statement. Each of the reporting persons may be deemed to be a member of a group with respect to the Issuer or securities of the Issuer for the purposes of Section 13(d) or 13(g) of the Act. Each of the reporting persons declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, (i) acting (or has agreed or is agreeing to act together with any other person) as a partnership, limited partnership, syndicate, or other group for the purpose of acquiring, holding, or disposing of securities of the Issuer or otherwise with respect to the Issuer or any securities of the Issuer or (ii) a member of any group with respect to the Issuer or any securities of the Issuer.

(b)

Item 2(b). Address of Principal Business Office or, if None, Residence: The address of the principal business office of each of the reporting persons is 152 West 57th Street, FL 20, New York, NY 10019

(c)

Item 2(c). Citizenship: See Item 4 on the cover page(s) hereto.

(d)

Item 2(d). Title of Class of Securities: Common Stock, par value $0.001 per share ("Common Stock")

(e)

Item 2(e). CUSIP Number: 23254L801 Item 3. If This Statement is Filed Pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), Check Whether the Person Filing is a: (a) Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o). (b) Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c). Page 6 of 9 CUSIP No . 23254L801 (c) Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c). (d) Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8). (e) An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E); (f) An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F); (g) A parent holding company or control person in accordance with §240.13d-1(b)(ii)(G); (h) A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); (i) A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3); (j) Group, in accordance with §240.13d-1(b)(1)(ii)(J). Item 4. Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. The information as of the date of the event which requires filing of this statement required by Items 4(a) – (c) is set forth in Rows 5 – 11 of the cover page for each Reporting Person listed above and is incorporated by reference for each such Reporting Person. The percentage set forth in Row 11 of the cover page for each Reporting Person is based on 1,019,310 shares of Common Stock outstanding as reported in the Issuers Form 424(b)(5) dated December 21, 2023, and filed with the Securities and Exchange Commission on December 26, 2023. Pursuant to the terms of the securities purchase agreement entered into between the Fund and the Issuer, the Fund purcha

View Full Filing

View this SC 13G filing on SEC EDGAR